Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical / R & D

Set Alert for Clinical R&D

New NHS England Processes To Tackle Uncertainties And Delays In Setting Up Clinical Trial Sites

A new "standard charging methodology" is to be introduced across NHS England to allow drug and device clinical trials to get underway faster. Presently, there can be a difference of up to nine months between confirmations being issued by each NHS hospital taking part in a multi-site trial.

Clinical Trials Policy & Regulation United Kingdom
Advertisement

Clinical Trials

Set Alert for Clinical Trials

Latest From Clinical Trials

QUOTED. May 18, 2018. William Abraham.

Results of a study showed that Impulse Dynamics' Optimizer device significantly improved exercise tolerance and quality of life in certain heart-failure patients. See what principal investigator (and cardiologist) William Abraham of Ohio State University said about those patients here.

Quoted Clinical Trials

HRS 2018: Optimizer Cardiac Contractility Device Helps Subset Of Heart-Failure Patients

The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.

Clinical Trials Approvals

iSTAR's Glaucoma Micro Device Shines In Early Follow-Up

iSTAR Medical reported six-month clinical trial data supporting its latest micro-invasive glaucoma surgery device, MINIject.

Ophthalmology Innovation
See All

New Technology

Set Alert for New Technology

Latest From Innovation

iSTAR's Glaucoma Micro Device Shines In Early Follow-Up

iSTAR Medical reported six-month clinical trial data supporting its latest micro-invasive glaucoma surgery device, MINIject.

Ophthalmology Innovation

Starts & Stops: May 7-13, 2018

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between May 7 and 13, 2018, including announcements from BioCardia, Akili Interactive Labs, Arch Therapeutics, and Acutus Medical.

Starts & Stops Clinical Trials

Global Device Approvals, Weekly Snapshot: May 7-13, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.

Approvals Research & Development
See All

Approvals

Set Alert for Approvals

Latest From Approvals

QUOTED. May 18, 2018. William Abraham.

Results of a study showed that Impulse Dynamics' Optimizer device significantly improved exercise tolerance and quality of life in certain heart-failure patients. See what principal investigator (and cardiologist) William Abraham of Ohio State University said about those patients here.

Quoted Clinical Trials

HRS 2018: Optimizer Cardiac Contractility Device Helps Subset Of Heart-Failure Patients

The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.

Clinical Trials Approvals

BTG Heads To Panel Next Month For Emphysema Device

A PMA for the PneumRx ELEVAIR endobronchial coil system will be considered by a US FDA advisory panel in June, but there will likely be some questions about the data.

Advisory Committees Approvals
See All
UsernamePublicRestriction

Register